نتایج جستجو برای: maintenance chemotherapy

تعداد نتایج: 257449  

Journal: : 2023

Aim to study the frequency of BRCA1/2 gene mutations , efficacy ovarian cancer therapy depending on presence as well olaparib maintenance in BRCAassociated cancer. Material and Methods. The retrospective analysis included 355 patients with high-grade, stage I–IV serous examination for a mutation was carried out within framework program “Improvement molecular genetic diagnostics Russian Federati...

Journal: :Journal of cancer research and therapeutics 2015
Mina Islambulchilar Iraj Asvadi Zohreh Sanaat Ali Esfahani Mohammadreza Sattari

OBJECTIVE The purpose of our study was to evaluate the effect of oral taurine supplementation on the incidence of chemotherapy-induced adverse drug reactions during chemotherapy in young adults with acute lymphoblastic leukemia (ALL). MATERIALS AND METHODS Forty young adult (aged over 16 years) with ALL, at the beginning of maintenance course of their chemotherapy, were recruited to the study...

2014
Yu-Mei Zhang Yong-Qiang Li Zhi-Hui Liu Xiao-Li Liao Rong Liang Yan Lin Chun-Ling Yuan Si-Na Liao Chao-Yong Liang Qian Li Le-Qun Li

Bevacizumab is a recombinant humanized monoclonal antibody used for multiple solid tumors in recent years, including lung cancer (Gentzler et al., 2013; Smith et al., 2013). At present, maintenance chemotherapy is a new perspective for advanced non-small cell lung cancer (NSCLC), which refers to the maintenance therapy in a certain period of induction chemotherapy to achieve the maximum tumor r...

Journal: :Anticancer research 2012
Motohiro Tamiya Akihiro Tamiya Keiko Nakao Kazuhiro Asami Kyoichi Okishio Morita Satomu Takayuki Shiroyama Naoko Morishita Hidekazu Suzuki Shinji Sasada Norio Okamoto Tomoya Kawaguchi Masashi Kobayashi Shinji Atagi Tomonori Hirashima Ichiro Kawase

BACKGROUND Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. PATIENT AND METHODS Medical records of patients with non-squamous NSCLC who received CP plus BEV between November 2009 and September 2011 and experienced progression after at least one pl...

2013
Siow Ming Lee Allan Hackshaw

There are few predictive biomarkers for antiangiogenic trials in lung cancer. We examine a potential treatment strategy in which a patient group is enriched using both histology and an early assessment of response during standard chemotherapy, and where a new agent is given for the remainder of chemotherapy and as maintenance. We performed a retrospective analysis of 722 stage IIIB/IV non-small...

Journal: :Haematologica 2007
Mathilde Hunault Malgorzata Truchan-Graczyk Denis Caillot Jean-Luc Harousseau Serge Bologna Chantal Himberlin Denis Guyotat Christian Berthou Philippe Casassus Laurence Baranger Marie-Christine Béné Norbert Ifrah Emmanuel Gyan

BACKGROUND AND OBJECTIVES T-lymphoblastic lymphoma is an infrequent disease usually treated as T-acute lymphoblastic leukemia with an induction chemotherapy course and sequential reinduction and maintenance chemotherapy. The T-LBL/ALL-GOELAL02 study evaluated the impact of randomized reinduction chemotherapy against intensified conditioning followed by autologous stem cell transplantation (ASCT...

2011
Giuseppe Avvisati

Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of early mortality. As a consequence, as soon as the diagnosis is suspected based upon cytologic criteria, it is necessary to start all- trans retinoic acid (ATRA) treatment without delay. For patients with newly diagnosed APL, induction therapy with ATRA plus anthracycline based chemotherapy is recommended. At p...

Journal: :International Journal of Medical Sciences 2008
Armelle Dufresne Xavier Pivot Christophe Tournigand Thomas Facchini Thierry Alweeg Loic Chaigneau Aimery De Gramont

The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید